Drug Trial Radar · NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
404
Planned (sponsor's estimate)
Start
Dec 5, 2023
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- BriaCell Therapeutics CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Conditions
- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer
Interventions
SV-BR-1-GMBiological
SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
CyclophosphamideDrug
Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
Interferon infiltration of the inoculation siteDrug
Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
RetifanlimabDrug
Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
Treatment of Physician's ChoiceDrug
Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 60 months
Locations
79 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic-Comprehensive Cancer Center-Breast Clinic
Phoenix, Arizona · Recruiting
University of Arizona-Cancer Center
Tucson, Arizona · Recruiting
Los Angeles cancer Network_Anaheim
Anaheim, California · Recruiting
Comprehensive Blood and Cancer Center
Bakersfield, California · Recruiting
Cedars-Sinai Cancer Beverly Hills
Beverly Hills, California · Recruiting
Los Angeles Cancer Network_Corona
Corona, California · Recruiting
Los Angeles cancer Network_Fountain Vallley
Fountain Valley, California · Recruiting
Los Angeles Cancer Network_Glendale
Glendale, California · Recruiting
Hoag Hospital Center
Irvine, California · Recruiting
Hoag Hospital Irvine
Irvine, California · Recruiting
Los Angeles Cancer Network
Los Angeles, California · Recruiting
Cedars-Sinai Cancer at Cedars-Sinai Medical Facility
Los Angeles, California · Recruiting
Los Angeles Cancer Network_Century City
Los Angeles, California · Recruiting
UCLA-Hematology/Oncology Medical Plaza
Los Angeles, California · Recruiting
UCLA-Hematology/Oncology_LA 2
Los Angeles, California · Recruiting
UCLA-Hematology/Oncology_LA
Los Angeles, California · Recruiting
Los Angeles Cancer Network_Pasadena
Pasadena, California · Recruiting
Los Angeles cancer Network_Riverside
Riverside, California · Recruiting
UC San Diego
San Diego, California · Recruiting
St. John's Cancer Center
Santa Monica, California · Recruiting
UCLA-Department of Medicine Hematology/Oncology-Parkside
Santa Monica, California · Recruiting
UCLA-Hetamtology/Oncology_S Monica
Santa Monica, California · Recruiting
Torrance Memorial Cancer Center
Torrance, California · Recruiting
Los Angeles Cancer Network_Valley Pres
Van Nuys, California · Recruiting
Cedars-Sinai Breast Health Services Building
West Hollywood, California · Recruiting
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut · Recruiting
University of Miami _SCCC - Aventura
Aventura, Florida · Recruiting
University of Miami-SCCC-Lennar
Coral Gables, Florida · Recruiting
University of Miami_SCCC-Coral Springs
Coral Springs, Florida · Recruiting
University of Miami Hospital and Clinics - Deerfield Beach
Deerfield Beach, Florida · Recruiting
University of Miami_SCCC-Hollywood
Hollywood, Florida · Recruiting
Mayo Clinic Florida-Comprehensive Cancer Center
Jacksonville, Florida · Recruiting
University Of Miami-SCCC-Miami
Miami, Florida · Recruiting
University of Miami_SCCC - Kendall
Miami, Florida · Recruiting
Advent Health - Orlando
Orlando, Florida · Recruiting
University of Miami-SCCC-Plantation
Plantation, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Southern Illinois University-Simmons
Springfield, Illinois · Recruiting
Carle Foundation Cancer Institute-Urbana
Urbana, Illinois · Recruiting
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.